Key facts
- It has raised $1.4M; the latest was Seed Round ($1.3M) in Jun 2025.
- Notable investors include Venture Kick, Boldbrain, Claves Investments, SICTIC, Sintetica — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for InkVivo
- ·The full record, as it builds
Funding rounds
No funding rounds for InkVivo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InkVivo
Developer of drug delivery systems designed for the localized and temporal release of various active ingredients, including small molecules, biologics, and micronutrients. The company's targeted and sustained release technology allows for more effective treatments with reduced dosing frequency and minimized side effects, enabling pharmaceutical, nutraceutical, and veterinary industries to regulate the release of ingredients.
- Sector
- Healthcare
- HQ
- Lugano, Switzerland
- Founded
- 2020
- Employees
- 8
- Website
- inkvivo.tech/
- Ownership
- Privately Held (backing)
InkVivo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InkVivo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InkVivo in its N-PORT filings yet. We sweep new filings monthly.